Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Eventide Healthcare & Life Sciences Fund CLASS I SHARES (ETIHX)

27.13
Net Asset Value
+0.11%
1 Day
+28.88%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
1.50%
Expense Ratio
--
Morningstar Risk Rating™
Investment Objective The investment seeks to provide long-term capital appreciation. Under normal market conditions, the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It is non-diversified.

Performance

1 month+3.20% 3 years--
3 months+17.72% 5 years--
1 year+71.63% Since inception+47.02%
Data through --

Peer Comparisonvs. Health

 ETIHXCategory
Performance 5-yr return--+26.59%
Expense ratio1.50%1.42%
Risk 5 year sharpe ratio--1.82
Net assets$301.7M$4.1B
Average market cap$1.7B$37.5B
Average P/E--25.5
Portfolio turnover33%33%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyEventide Funds
Fund manager & tenureFinny Kuruvilla / 2 Years
Minimal initial investment$100,000.00
Minimum IRA investment--

Holdings

U.S. stock80.54%
Cash15.06%
International stock3.51%
Fixed income0.89%
Other0.00%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
BLUE bluebird bio Inc4.19%
NBIX Neurocrine Biosciences Inc2.56%
CEMP Cempra Inc2.47%
VCYT Veracyte Inc2.41%
DYAX Dyax Corp2.38%
TTPH Tetraphase Pharmaceuticals Inc2.38%
TSRO TESARO Inc2.36%
FPRX Five Prime Therapeutics Inc2.35%
CMRX Chimerix Inc2.34%
BMRN Biomarin Pharmaceutical Inc2.34%